20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with cyclin d1 in 1 studies
| Studies (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Trials (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Recent Studies (post-2010) (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 640 | 13 | 233 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ives, HE; Liang, CJ; Ma, YH; Yang, CM | 1 |
1 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and cyclin d1
| Article | Year |
|---|---|
20-HETE inhibits the proliferation of vascular smooth muscle cells via transforming growth factor-beta.
Topics: Animals; Cell Proliferation; Cells, Cultured; Cyclin D1; DNA; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxyeicosatetraenoic Acids; Mitogen-Activated Protein Kinase Kinases; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Rats; Transforming Growth Factor beta | 2008 |